Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.7% - Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 6.7% on Friday . The company traded as high as $7.05 and last traded at $7.03. Approximately 1,938,599 shares traded hands during trading, a decline of 68% from the average daily volume of 6,136,487 shares. The stock had previously closed at $6.59.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RXRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, November 20th. Jefferies Financial Group cut their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Finally, Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $9.25.

Recursion Pharmaceuticals Price Performance

The firm's fifty day moving average price is $6.59 and its 200-day moving average price is $7.35. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.30 billion, a P/E ratio of -5.28 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue was up 147.6% on a year-over-year basis. During the same period last year, the business earned ($0.43) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares in the company, valued at $53,985,103.32. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 134,235 shares of company stock valued at $895,538 in the last 90 days. Insiders own 15.75% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the second quarter worth about $5,769,000. Pier 88 Investment Partners LLC increased its position in Recursion Pharmaceuticals by 442.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company's stock valued at $882,000 after buying an additional 109,210 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Recursion Pharmaceuticals by 6,439.6% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company's stock valued at $1,274,000 after buying an additional 167,302 shares during the last quarter. Scientech Research LLC bought a new stake in Recursion Pharmaceuticals in the second quarter worth $1,052,000. Finally, Ghisallo Capital Management LLC bought a new stake in Recursion Pharmaceuticals in the second quarter worth $8,250,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.